The information in this section is intended for visitors outside the United States.
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries
Gilead Sciences Announces Second Quarter 2014 Financial Results
2013 Annual Review